Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSPI 3260309 trials

SK biopharmaceuticals Co., Ltd.

Official website

KOSPI-listed drugmaker behind epilepsy treatment cenobamate (XCOPRI) and sleep disorder drug solriamfetol (SUNOSI).

As of 2026-10-11, SK biopharmaceuticals Co., Ltd. has 30 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2011 and listed on KOSPI in 2020, SK Biopharmaceuticals is a drug developer focused on central nervous system disorders, with SK Group's drug R&D dating back to 1993. It holds the self-developed epilepsy treatment cenobamate (marketed as XCOPRI in the US and ONTOZRY in Europe) and the out-licensed sleep disorder drug solriamfetol (marketed as SUNOSI in the US), and has signed cenobamate license-out agreements with partners including Angelini Pharma, Ono Pharmaceutical, and Knight Therapeutics. Consolidated 2025 revenue was KRW 706.7 billion, with cenobamate contributing KRW 683.0 billion (96.7%) and solriamfetol KRW 11.4 billion (1.6%); the company also secured targeted protein degradation (TPD) technology through its acquisition of SK Lifescience Labs (formerly ProteoVant) and entered the radiopharmaceutical therapy (RPT) field with candidates SKL35501 and SKL37321.

Products & technology

  • CenobamateEpilepsy treatment
  • SolriamfetolSleep disorder (narcolepsy, etc.) treatment

Clinical trials

data.go.kr

9 MFDS clinical trial authorisations · 2018–2026 (Phase 3 5 · Phase 1 4)

  • Phase 1SKL35501 주2026-01-29

    3 trial sites

  • Phase 1YKP3089 정2023-12-12

    4 trial sites

  • Phase 3YKP3089 정2023-08-28

    5 trial sites

  • Phase 3YKP3089 정2023-03-29

    5 trial sites

  • Phase 3카리스바메이트 (YKP509) 경구용 현탁액2022-11-10

    6 trial sites

  • Phase 3YKP3089 정2022-02-23

    6 trial sites

  • Phase 3YKP3089 정2020-09-09

    14 trial sites

  • Phase 1SKL20540캡슐2018-01-12

    1 trial site

  • Phase 1YKP3089 정2018-01-10

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 33 more trials

R&D and key agreements

Source: DART corporate disclosure

TPD(표적단백질분해 치료제) · 항암(CNS 역량 확장) · 기술 확보 단계 · Technology acquired via acquisition of SK Lifescience Labs (formerly ProteoVant)

RPT(방사성의약품) - SKL35501, SKL37321 · 항암 · 후보물질 도입 · Radiopharmaceutical candidates introduced

카리스바메이트 · 중국 지역 개발 준비중 · Licensed to Ignis Therapeutics (Nov 11, 2021)

SKL13865 · 중국 지역 개발 준비중 · Licensed to Ignis Therapeutics (Nov 11, 2021)

Key disclosures

KRX KIND via OpenDART
Show 23 more events

Publications

PubMed · affiliation-matched
Show 20 more publications

Patents

KIPRIS · applicant-matched
Show 140 more patents

AI reads

MAA server logs · IP-verified
10
Times AI engines pulled SK biopharmaceuticals Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

0
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

10
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

3
live 0
Last 7 days
5
live 0
Last 30 days
10
live 0
All time
  • OpenAIOAI-SearchBot5
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • PerplexityPerplexityBot1
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 6, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SK biopharmaceuticals Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition